Ticotyle 600 Injection contains Teicoplanin, a glycopeptide antibiotic used for the treatment of serious Gram-positive bacterial infections. It is particularly effective against resistant organisms such as MRSA and other difficult-to-treat infections.
Teicoplanin works by inhibiting bacterial cell wall synthesis, leading to the destruction of bacteria. Its strong activity against Gram-positive pathogens makes it a reliable choice in severe and hospital-acquired infections.
This injection is widely used in hospital and critical care settings due to its long half-life, convenient dosing, and proven clinical efficacy. It is commonly prescribed in cases where other antibiotics may not be suitable.
With increasing antibiotic resistance and rising demand for advanced critical care medicines, this product offers strong market potential. Its hospital usage, high clinical demand, and effectiveness against resistant bacteria make it a valuable option for business growth in the anti-infective segment.
Common side effects may include pain or redness at the injection site, fever, rash, and nausea. Some patients may experience dizziness or headache. Rarely, allergic reactions, kidney function changes, or hearing disturbances may occur.
Ticotyle 600 Injection (Teicoplanin 600 mg) is indicated for the treatment of serious gram-positive bacterial infections, including skin and soft tissue infections, bone and joint infections, respiratory tract infections, urinary tract infections, and septicemia. It is also used in infections caused by resistant organisms such as MRSA.
This medication should be administered under medical supervision. Dose adjustment may be required in patients with renal impairment. Inform your doctor about any history of allergy to glycopeptide antibiotics. Regular monitoring of kidney function and blood parameters is recommended during prolonged therapy.
Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children. Use immediately after reconstitution as directed.